The Effects of Glucose Control and Weight Loss Between Beinaglutide and Dulaglutide in Type 2 Diabetes With Overweight or Obesity.

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.

Also called NCT05005741

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05005741
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05005741. Randomized; no masking; primary purpose treatment. Start 2021-05-01 (actual); primary completion 2023-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Effects of Glucose Control and Weight Loss Between Beinaglutide and Dulaglutide in Type 2 Diabetes With Overweight or Obesity.
Condition
Diabetes Mellitus, Type 2
Condition
Overweight or Obesity
Intervention (Drug)
Beinaglutide
Intervention (Drug)
Dulaglutide
Lead sponsor
Second Xiangya Hospital of Central South University (class: other)
Collaborator
Guangdong Provincial People's Hospital (class: other)
Collaborator
First Affiliated Hospital of Harbin Medical University (class: other)
Collaborator
The First Affiliated Hospital of Henan University of Science and Technology (class: other)

Record details

Record id
cardio:ct-nct05005741
Content hash
6527cced9ba6f2a125e5f01637f283fdb3fb0c65a708a7c6c672fed1cd2ff56b